<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337465</url>
  </required_header>
  <id_info>
    <org_study_id>CASE6Y14</org_study_id>
    <nct_id>NCT02337465</nct_id>
  </id_info>
  <brief_title>KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer</brief_title>
  <official_title>Integrated 3D X-ray and Ultrasound Guided Radiation Therapy of Soft Tissue Targets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies if kilo-voltage cone beam computed tomography (KV-CBCT) and&#xD;
      ultrasound imaging works in guiding radiation therapy in patients with prostate, liver, or&#xD;
      pancreatic cancer. Computer systems, such as KV-CBCT and ultrasound imaging, allow doctors to&#xD;
      create a 3-dimensional picture of the tumor may help in planning radiation therapy and may&#xD;
      result in more tumor cells being killed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To investigate the feasibility of combining on-board cone beam computed tomography (CBCT)&#xD;
      with ultrasound imaging to overcome the shortcomings of CBCT or ultrasound imaging alone for&#xD;
      imaging guided radiotherapy delivery.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo ultrasound imaging prior to and during radiation therapy. Patients also&#xD;
      undergo kilo-voltage cone beam computed tomography prior to radiation therapy.&#xD;
&#xD;
      Update (2021/02/04): Removed secondary outcome &quot;Incidence of Adverse Events Related to the&#xD;
      Ultrasound Probe&quot;. Per PI: Study initially intended to involve a non-FDA approved probe for&#xD;
      use with liver patients but removed this section.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2015</start_date>
  <completion_date type="Actual">December 14, 2019</completion_date>
  <primary_completion_date type="Actual">December 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Ultrasound Images Which Are Clinically Adequate for Treatment Set-up</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Percentage of ultrasound images which are clinically adequate for treatment set-up in the judgment of the treating physician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Able to Have the Ultrasound Probe Attached During the Entire Treatment Course</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Proportion of participants able to have the ultrasound probe attached during the entire treatment course</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Quality of plans for patients not affected in the presence of the ultrasound probe, defined as no more than a 2% decrease in tumor coverage, and also no more than a 2% increase in the dose to the most critical normal tissue for that tumor location</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Adult Liver Carcinoma</condition>
  <condition>Malignant Pancreatic Neoplasm</condition>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cone-Beam Computed Tomography</intervention_name>
    <description>Undergo kilo-voltage cone beam computed tomography</description>
    <arm_group_label>Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Ultrasound-Guided Radiation Therapy</intervention_name>
    <description>Undergo ultrasound-guided radiation therapy</description>
    <arm_group_label>Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)</arm_group_label>
    <other_name>3D Ultrasound-Guided Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have either 1) cancer involving the liver by biopsy or radiographic&#xD;
             criteria, or 2) prostate cancer by biopsy, with the intent of undergoing definitive&#xD;
             dose radiation therapy to targets within the liver, or prostate. Patients with&#xD;
             prostatectomy receiving post-operative radiotherapy are also eligible.&#xD;
&#xD;
          -  Karnofsky performance status (PS) â‰¥ 70&#xD;
&#xD;
          -  Subjects must have the ability to understand and the willingness to sign a written&#xD;
             informational form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with uncontrolled inter-current illness or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Xia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Stephans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <results_first_submitted>February 4, 2021</results_first_submitted>
  <results_first_submitted_qc>February 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02337465/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02337465/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (KV-CBCT, Ultrasound-guided Radiation Therapy)</title>
          <description>Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.&#xD;
Cone-Beam Computed Tomography: Undergo kilo-voltage cone beam computed tomography&#xD;
3-Dimensional Ultrasound-Guided Radiation Therapy: Undergo ultrasound-guided radiation therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (KV-CBCT, Ultrasound-guided Radiation Therapy)</title>
          <description>Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.&#xD;
Cone-Beam Computed Tomography: Undergo kilo-voltage cone beam computed tomography&#xD;
3-Dimensional Ultrasound-Guided Radiation Therapy: Undergo ultrasound-guided radiation therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Ultrasound Images Which Are Clinically Adequate for Treatment Set-up</title>
        <description>Percentage of ultrasound images which are clinically adequate for treatment set-up in the judgment of the treating physician</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (KV-CBCT, Ultrasound-guided Radiation Therapy)</title>
            <description>Participants undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Participants also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.&#xD;
Cone-Beam Computed Tomography: Undergo kilo-voltage cone beam computed tomography&#xD;
3-Dimensional Ultrasound-Guided Radiation Therapy: Undergo ultrasound-guided radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Ultrasound Images Which Are Clinically Adequate for Treatment Set-up</title>
          <description>Percentage of ultrasound images which are clinically adequate for treatment set-up in the judgment of the treating physician</description>
          <population>Participants enrolled on study</population>
          <units>Percent of images</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Able to Have the Ultrasound Probe Attached During the Entire Treatment Course</title>
        <description>Proportion of participants able to have the ultrasound probe attached during the entire treatment course</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (KV-CBCT, Ultrasound-guided Radiation Therapy)</title>
            <description>Participants undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Participants also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.&#xD;
Cone-Beam Computed Tomography: Undergo kilo-voltage cone beam computed tomography&#xD;
3-Dimensional Ultrasound-Guided Radiation Therapy: Undergo ultrasound-guided radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Able to Have the Ultrasound Probe Attached During the Entire Treatment Course</title>
          <description>Proportion of participants able to have the ultrasound probe attached during the entire treatment course</description>
          <population>Participants enrolled on study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe</title>
        <description>Quality of plans for patients not affected in the presence of the ultrasound probe, defined as no more than a 2% decrease in tumor coverage, and also no more than a 2% increase in the dose to the most critical normal tissue for that tumor location</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Participants enrolled on study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (KV-CBCT, Ultrasound-guided Radiation Therapy)</title>
            <description>Participants undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Participants also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.&#xD;
Cone-Beam Computed Tomography: Undergo kilo-voltage cone beam computed tomography&#xD;
3-Dimensional Ultrasound-Guided Radiation Therapy: Undergo ultrasound-guided radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe</title>
          <description>Quality of plans for patients not affected in the presence of the ultrasound probe, defined as no more than a 2% decrease in tumor coverage, and also no more than a 2% increase in the dose to the most critical normal tissue for that tumor location</description>
          <population>Participants enrolled on study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No plan to collect adverse event data (per-protocol)</desc>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (KV-CBCT, Ultrasound-guided Radiation Therapy)</title>
          <description>Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.&#xD;
Cone-Beam Computed Tomography: Undergo kilo-voltage cone beam computed tomography&#xD;
3-Dimensional Ultrasound-Guided Radiation Therapy: Undergo ultrasound-guided radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ping Xia</name_or_title>
      <organization>Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center</organization>
      <phone>1-866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

